| Abstrakt: |
Keywords for this news article include: Imperial College London, London, United Kingdom, Europe, Anticonvulsants, Pharmaceuticals, Vulvodynia, Women's Health, Gabapentin Therapy, Drugs and Therapies, Health and Medicine, Central Nervous System Agents, Vulvar Diseases and Conditions, Gamma-aminobutyric Acid Analogs, Urogenital Diseases and Conditions, Female Genital Diseases and Conditions. Anticonvulsants, Central Nervous System Agents, Drugs and Therapies, Female Genital Diseases and Conditions, Gabapentin Therapy, Gamma-aminobutyric Acid Analogs, Health and Medicine, Pharmaceuticals, Urogenital Diseases and Conditions, Vulvar Diseases and Conditions, Women's Health, Vulvodynia Keywords: Anticonvulsants; Central Nervous System Agents; Drugs and Therapies; Female Genital Diseases and Conditions; Gabapentin Therapy; Gamma-aminobutyric Acid Analogs; Health and Medicine; Pharmaceuticals; Urogenital Diseases and Conditions; Vulvar Diseases and Conditions; Vulvodynia; Women's Health EN Anticonvulsants Central Nervous System Agents Drugs and Therapies Female Genital Diseases and Conditions Gabapentin Therapy Gamma-aminobutyric Acid Analogs Health and Medicine Pharmaceuticals Urogenital Diseases and Conditions Vulvar Diseases and Conditions Vulvodynia Women's Health 663 663 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on vulvodynia is now available. [Extracted from the article] |
